EP1904037A1 - Prolonged release formulation of active principles having a ph-dependent solubility - Google Patents
Prolonged release formulation of active principles having a ph-dependent solubilityInfo
- Publication number
- EP1904037A1 EP1904037A1 EP06778663A EP06778663A EP1904037A1 EP 1904037 A1 EP1904037 A1 EP 1904037A1 EP 06778663 A EP06778663 A EP 06778663A EP 06778663 A EP06778663 A EP 06778663A EP 1904037 A1 EP1904037 A1 EP 1904037A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- layer
- formulation according
- agent
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 238000009472 formulation Methods 0.000 title claims abstract description 58
- 230000001419 dependent effect Effects 0.000 title claims abstract description 9
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 5
- 239000002535 acidifier Substances 0.000 claims abstract description 22
- 239000011159 matrix material Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract description 3
- 239000010410 layer Substances 0.000 claims description 49
- 239000004480 active ingredient Substances 0.000 claims description 34
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 27
- 229960001475 zolpidem Drugs 0.000 claims description 24
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical group N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 24
- 239000012730 sustained-release form Substances 0.000 claims description 20
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 19
- 238000013268 sustained release Methods 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 13
- 239000003086 colorant Substances 0.000 claims description 12
- 150000008043 acidic salts Chemical class 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- VXRDAMSNTXUHFX-CEAXSRTFSA-N zolpidem tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 VXRDAMSNTXUHFX-CEAXSRTFSA-N 0.000 claims description 9
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 8
- 238000009501 film coating Methods 0.000 claims description 8
- 229960001021 lactose monohydrate Drugs 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000013265 extended release Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 5
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 5
- -1 5-chloro-2-methoxyphenyl Chemical group 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 4
- 239000008119 colloidal silica Substances 0.000 claims description 4
- 239000001472 potassium tartrate Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- JMEVHYCNAPFOAB-UHFFFAOYSA-N 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-N 0.000 claims description 2
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 claims description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001938 Vegetable gum Polymers 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 229960003009 clopidogrel Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000012738 indigotine Nutrition 0.000 claims description 2
- 239000004179 indigotine Substances 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960001144 mizolastine Drugs 0.000 claims description 2
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000002524 monosodium citrate Substances 0.000 claims description 2
- 235000018342 monosodium citrate Nutrition 0.000 claims description 2
- 235000019321 monosodium tartrate Nutrition 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims 6
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims 2
- JDLYOFUDIKMYBL-UHFFFAOYSA-N 2-[7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1-yl]acetamide Chemical compound C=1C(=O)N(CC(=O)N)C2=CC(F)=CC=C2C=1CCN(CC1)CCN1C1=NC=CC2=C1C=CS2 JDLYOFUDIKMYBL-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920003174 cellulose-based polymer Polymers 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960005111 zolpidem tartrate Drugs 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RTMBGDBBDQKNNZ-UHFFFAOYSA-L C.I. Acid Blue 3 Chemical compound [Ca+2].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=C(O)C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1.C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=C(O)C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 RTMBGDBBDQKNNZ-UHFFFAOYSA-L 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WXLFIFHRGFOVCD-UHFFFAOYSA-L azophloxine Chemical compound [Na+].[Na+].OC1=C2C(NC(=O)C)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 WXLFIFHRGFOVCD-UHFFFAOYSA-L 0.000 description 1
- 235000012733 azorubine Nutrition 0.000 description 1
- TVWOWDDBXAFQDG-DQRAZIAOSA-N azorubine Chemical compound C1=CC=C2C(\N=N/C3=C(C4=CC=CC=C4C(=C3)S(O)(=O)=O)O)=CC=C(S(O)(=O)=O)C2=C1 TVWOWDDBXAFQDG-DQRAZIAOSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940081543 potassium bitartrate Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000004180 red 2G Substances 0.000 description 1
- 235000012739 red 2G Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Definitions
- the present invention relates to a new extended-release formulation, usable for various active ingredients of drugs.
- the invention relates in particular to a novel formulation adapted for the sustained release of active ingredients which have a pH-dependent solubility and which are used in the form of base or addition salts of these bases.
- the invention relates to a sustained-release formulation usable with zolpidem, but is not limited to this single active ingredient.
- Zolpidem is a short-acting hypnotic agent suitable for the implementation of the formulation according to the invention.
- Zolpidem is an active substance derived from the chemical family of imidazopyridines. It is administered orally in tablet form.
- Zolpidem acts rapidly, with a duration of action of up to 6 hours.
- zolpidem has both rapid absorption and bioavailability. Indeed, 70% of zolpidem are available after oral administration at the therapeutic dose used, which varies between 5 and 10 mg in conventional forms.
- the maximum plasma concentration is reached between 0.5 and 3 hours and the half-life time is short, with an average of 2.4 hours.
- Immediate release administration forms of zolpidem are already known. They allow the formulation to disintegrate rapidly in the gastrointestinal tract, dissolve in the fluids of the tract by allowing the active ingredient to be subsequently absorbed and produce its pharmacological effect by inducing sleep in the patient.
- a zolpidem extended-release form of administration is also known, which makes it possible to release the active ingredient in a period compatible both with the desired time of sleep and that necessary for the elimination of the drug from the human body.
- a sustained release form is described in particular in EP-A-1 135 125 which describes a sustained release tablet, comprising a single layer containing the active ingredient embedded in the mass of a polymeric material based on cellulose. This polymeric material, which forms in contact with aqueous media a matrix, allows a slowing down of the dissolution of the active ingredient, which can thus produce its pharmacological effect more slowly.
- EP-A-1,135,125 also discloses other embodiments of zolpidem extended release formulations.
- a multilayer tablet in which zolpidem is present in two entities, an immediate release entity, for example an external entity, and a sustained release entity, for example internal.
- the sustained-release entity comprises a layer or core of polymeric material, particularly a cellulose-based polymer, releasing the amount of zolpidem it contains more slowly than the immediate-release entity.
- the total of the two doses of zolpidem contained in each entity corresponds to the dose that it is desired to administer to the patient.
- the document EP-A-1 135 125 describes the use of an acidifying agent, for example acid citric, tartaric or fumaric.
- an acidifying agent for example acid citric, tartaric or fumaric.
- local micro-pH or local pH means the pH existing in the immediate environment of the formulation, as it dissolves in the gastrointestinal tract.
- This degradation of the polymer by the acidifying agent can then lead to a reduced stability of the formulations, and may oblige the manufacturer to recommend stricter storage conditions, with respect to heat and humidity, or to provide for a more watertight packaging system.
- the invention aims to solve this drawback by proposing a sustained release formulation to maintain a local pH low enough to ensure solubility of the active ingredient independent of pH, and without degradation of the polymer present in the matrix, nor a negative impact on the stability of the active ingredient.
- a first object of the invention relates to such a sustained release formulation.
- the formulation of the invention for a sustained release of an active ingredient having a pH-dependent solubility comprises a matrix excipient based on hydrophilic polymer which contains a determined dose of active ingredient, and is characterized in that it comprises one or more acidifying agents in the form of an acidic salt of an organic acid.
- the acidic salt of the acidifying agent may be, for example, an acidic salt of citric, tartaric, fumaric, succinic or malic acid, as well as mixtures thereof.
- acidifying agent in the form of acidic salt examples include monopotassic tartrate (or potassium bitartrate), monosodium tartrate, monosodium citrate, bisodium citrate, and / or mixtures thereof.
- monopotassium tartrate has the additional advantage of not having any influence on the stability of tartrate or zolpidem hemitartrate.
- the percentage of acidifying agent is between about 2% and about 10% by weight, calculated with respect to the total weight of the formulation, for example between about 4 % and about 8% by weight.
- the invention is not limited to the formulation of zolpidem.
- Other active ingredients whose solubility depends on the surrounding pH can be used in the context of the invention. This is the case in particular for basic active ingredients present in the formulation in free base or salt form, these active ingredients being insoluble or poorly soluble in aqueous medium at neutral pH, and when the pKa value is greater than 2.
- active ingredients that can be used with the invention are N- [2 - [(4-aminocarbonyl) pyrimidin-2-yl] amino] ethyl] -2 - [[3- [4- 5-chloro-2-methoxyphenyl) piperazin-1-yl] propyl] amino] pyrimidine-4-carboximide, 5- (8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin) hydrochloride.
- the active ingredients that can be used in the context of the invention may exist in the form of a base, an addition salt, in particular an acidic salt, a hydrate or a solvate salt, namely in the form of associations or combinations with one or more molecules of water or with a solvent.
- zolpidem can be used in the form of hemitartrate.
- the formulation of the invention comprises a matrix excipient allowing prolonged release of the active ingredient.
- hydrophilic polymer-based matrix excipients include cellulose and its derivatives, for example hydroxypropylmethylcellulose (hypromellose), hydroxyethylcellulose,
- Hydroxypropylcellulose carboxymethylcellulose, vegetable gums and their derivatives, derivatives of alginic acid, starch and its derivatives.
- the sustained-release formulation of the invention further comprises the conventional ingredients used in this type of formulation.
- the formulation of the invention may comprise one or more diluents, disintegrating agents, binding agents, lubricants, flow excipients, coloring agents chosen from those known to those skilled in the art.
- lactose and its derivatives for example lactose monohydrate, cellulose and its derivatives, for example microcrystalline cellulose, mannitol, calcium hydrogen phosphate, tricalcium phosphate, calcium sulphate, starch and its derivatives, in particular pregelatinized starch, crosslinked starch.
- binding agents mention may be made of hydroxypropyl methylcellulose of low molecular weight and its derivatives, for example Methocel ® E5, povidones for example Kollidon K30.
- disintegrating agents include starch and its derivatives, for example sodium carboxymethyl starch, crosslinked povidone, croscarmellose, hydroxypropylcellulose low molecular weight.
- lubricating agents include stearic acid and its salts, for example, magnesium stearate, sodium stearyl fumarate, glyceryl behenate.
- silica and its derivatives for example anhydrous colloidal silica, colloidal silicon dioxide, talc.
- coloring agents By way of examples of coloring agents, mention may be made of metal oxides, for example iron oxides, in particular red or yellow iron, indigotine, curcumin, riflavin, tartrazine and azorubine. , carminates, erythosine, red 2G, patent blue V, chlorophylls, chlorophyll copper complexes, carotenoids, paprika extracts, anthocyanins, titanium dioxide, aluminum, silver gold, as well as other pharmaceutically acceptable coloring agents.
- metal oxides for example iron oxides, in particular red or yellow iron, indigotine, curcumin, riflavin, tartrazine and azorubine.
- carminates erythosine, red 2G, patent blue V
- chlorophylls chlorophyll copper complexes
- carotenoids carotenoids
- paprika extracts anthocyanins
- titanium dioxide aluminum, silver gold, as well as other pharmaceutically acceptable coloring agents.
- the formulation of the invention comprises a film-coating layer.
- This film-coating layer may comprise one or more opacifying agents, plasticizing agents, dyes, as well as one or more excipients, film-forming polymers.
- ingredients are chosen from those known to those skilled in the art.
- opacifying agents mention may be made of titanium oxide;
- plasticizers include polyethylene glycol and its derivatives;
- excipients mention may be made of lactose and its derivatives, for example lactose monohydrate.
- film-forming polymer excipients mention may be made of hydroxypropylethylcellulose and polyvinyl alcohol.
- the formulation of the invention comprises a sustained release entity and, optionally, an immediate release entity.
- the immediate release entity is understood to mean a dose comprising a specific quantity of immediate-release active ingredient, such as, for example, an immediate-release tablet or pellet, or a plurality of these doses formulated in a capsule. or a tablet; an immediate release matrix in a tablet; an immediate release layer in a multilayer tablet; an immediate release coating layer in a coated tablet.
- sustained release entity is meant a dose comprising a fixed dose of sustained-release active ingredient, such as a sustained-release tablet, or more of these doses formulated in a capsule or tablet; a sustained release matrix in a tablet; a sustained release layer in a multilayered tablet.
- the unit dosage forms of the formulation of the invention include oral forms such as tablets, including multilayer, coated, core tablets; soft or hard capsules.
- the formulation of the invention consists of a multilayer tablet, in particular a two-layer tablet.
- the first layer is immediate release and comprises a dose of zolpidem, delivering by rapid disintegration in contact with water all of zolpidem it contains.
- the second layer is sustained release and also closes a dose of zolpidem, gradually delivering the active ingredient by erosion and diffusion.
- the contents of the active ingredient of each of the two layers may vary, generally the respective doses are of substantially the same size.
- the immediate release layer may contain from 40 to 55% of the total dose of active ingredient contained in the formulation, for example 48% of active ingredient, and the sustained-release layer may contain from 45 to 60% of the total dose of active ingredient contained in the formulation, for example 52%.
- the formulation of the invention comprises:
- a first immediate release layer comprising an active ingredient whose solubility is dependent on the pH, and one or more binding agents
- the first layer optionally comprising one or more other excipients such as diluents, disintegrating agents, lubricating agents, coloring agents
- a second sustained-release layer adjacent to the first layer, comprising an active ingredient whose solubility is dependent on the pH, one or more acidifying agents in the acid salt form and one or more matrix excipients, the second layer optionally comprising one or more several other excipients such as diluents, binding agents, lubricating agents, coloring agents.
- the first immediate release layer comprises, in percentage by weight relative to the total weight of the layer in question:
- binding agent from 0% to 5% by weight of binding agent
- coloring agent from 0% to 1% by weight of coloring agent.
- the second extended-release layer comprises, in percentage by weight relative to the total weight of the layer in question:
- the formulation may also comprise a film-coating layer, coating the first and the second layers.
- This coating layer may be made of commercially available compositions, such as products sold under the names OPADRY ® II 32F20797, OPADRY ® YS-1-1418 and generally comprises as main ingredients a load carrier, a polymeric binder, opacifying agent, a plasticizer, a coloring agent and a solvent.
- the excipients contained in the first and the second layer may be identical or different from each other, with the exception of the acidifying agent.
- compositions according to the invention may be prepared according to the methods known to those skilled in the art.
- Immediate-release tablets may be prepared by direct compression of mixtures of active ingredients in base form or salts with diluents, such as microcrystalline cellulose, mannitol, sorbitol, lactose. Other excipients, such as disintegrants or lubricants, may be added.
- the tablets may be prepared by granulation with water of a mixture of the active ingredient (s) with the appropriate diluents, disintegrating agents and binding polymer, and then calibration and drying of the granulate obtained. , addition of a lubricating agent, followed by compression on a compression machine.
- the sustained release tablets may be prepared by incorporation of matrix excipients into the formulation without disintegrating agents.
- matrix excipients are, for example, the hydrophilic polymers described above, for example based on cellulose, which swell in contact with water and prolongively release the active principle by diffusion through the swollen polymer network.
- Example 1 Preparation of a two-layer tablet containing a dose of 6.25 mg zolpidem.
- Example 2 Preparation of a two-layer tablet containing a dose of 12.5 mg of zolpidem.
- Example 3 Preparation of a two-layer tablet containing 12.5 mg of zolpidem tartrate and tartaric acid.
- dissolution medium 500 ml of degassed 0.01 M HCI
- FIGS. 1 and 2 The results obtained are represented in FIGS. 1 and 2, in which FIG. 1 represents the evolution of the dissolution profiles as a function of time, obtained with the formulation prepared according to example 3 (zolpidem tablet at 12, 5 mg containing as acidifying agent of tartaric acid), and FIG. 2 represents revolution of the dissolution profiles as a function of time, obtained with the formulation prepared according to Example 2 (12.5 mg zolpidem tablet containing as agent acidifier of monopotassium tartrate).
- Example 2 has a stability to heat and moisture greater than that of the formulation prepared according to Example 3.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention concerns a novel formulation for prolonged release of an active principle having a pH-dependent solubility. The inventive formulation comprises a matrix support based on hydrophilic polymer containing a specific dose of active principle, and further comprises on or more acidifying agents in the form of an acid salt of an organic acid.
Description
FORMULATION A LIBERATION PROLONGEE DE PRINCIPES ACTIFS DE MEDICAMENTSFORMULATION WITH PROLONGED RELEASE OF ACTIVE MEDICINAL PRINCIPLES
[0001] La présente invention se rapporte à une nouvelle formulation à libération prolongée, utilisable pour divers principes actifs de médicaments.The present invention relates to a new extended-release formulation, usable for various active ingredients of drugs.
[0002] L'invention se rapporte en particulier à une nouvelle formulation adaptée pour la libération prolongée de principes actifs qui présentent une solubilité dépendante du pH et qui sont utilisés sous forme de base ou de sels d'addition de ces bases. En particulier, l'invention se rapporte à une formulation à libération prolongée utilisable avec le zolpidem, mais n'est pas limitée à ce seul principe actif.The invention relates in particular to a novel formulation adapted for the sustained release of active ingredients which have a pH-dependent solubility and which are used in the form of base or addition salts of these bases. In particular, the invention relates to a sustained-release formulation usable with zolpidem, but is not limited to this single active ingredient.
[0003] Le zolpidem est un agent hypnotique à durée d'action courte approprié pour la mise en œuvre de la formulation selon l'invention. Le zolpidem est un principe actif dérivé de la famille chimique des imidazopyridines. Il est administré par voie orale sous forme de comprimé.Zolpidem is a short-acting hypnotic agent suitable for the implementation of the formulation according to the invention. Zolpidem is an active substance derived from the chemical family of imidazopyridines. It is administered orally in tablet form.
[0004] Le zolpidem agit rapidement, avec une durée d'action allant jusqu 'à 6 heures.[0004] Zolpidem acts rapidly, with a duration of action of up to 6 hours.
Les données pharmacodynamiques et pharmacocinétiques montrent que le zolpidem possède à la fois une absorption et une biodisponibilité rapides. En effet, 70 % du zolpidem sont disponibles après l'administration orale à la dose thérapeutique utilisée, qui varie entre 5 et 10 mg dans les formes conventionnelles.The pharmacodynamic and pharmacokinetic data show that zolpidem has both rapid absorption and bioavailability. Indeed, 70% of zolpidem are available after oral administration at the therapeutic dose used, which varies between 5 and 10 mg in conventional forms.
La concentration plasmatique maximale est atteinte entre 0,5 et 3 heures et le temps de demi-vie est court, avec une moyenne de 2,4 heures.The maximum plasma concentration is reached between 0.5 and 3 hours and the half-life time is short, with an average of 2.4 hours.
[0005] Des formes d'administration à libération immédiate du zolpidem sont déjà connues. Elles permettent à la formulation de se désagréger rapidement dans le tractus gastro-intestinal, de se dissoudre dans les fluides du tractus en permettant au principe actif d'être ensuite absorbé et de produire son effet pharmacologique en induisant le sommeil chez le patient.[0005] Immediate release administration forms of zolpidem are already known. They allow the formulation to disintegrate rapidly in the gastrointestinal tract, dissolve in the fluids of the tract by allowing the active ingredient to be subsequently absorbed and produce its pharmacological effect by inducing sleep in the patient.
[0006] On connaît également une forme d'administration à libération prolongée de zolpidem, permettant de libérer le principe actif dans une période compatible à la fois avec le temps désiré de sommeil et celui nécessaire à l'élimination du médicament du corps humain.
[0007] Une telle forme à libération prolongée est notamment décrite dans le document EP-A-1 135 125 qui décrit un comprimé à libération prolongée, comprenant une couche unique renfermant le principe actif noyé dans la masse d'un matériau polymérique à base de cellulose. Ce matériau polymérique, qui forme au contact des milieux aqueux une matrice, permet un ralentissement de la dissolution du principe actif, qui peut ainsi produire son effet pharmacologique plus lentement.[0006] A zolpidem extended-release form of administration is also known, which makes it possible to release the active ingredient in a period compatible both with the desired time of sleep and that necessary for the elimination of the drug from the human body. Such a sustained release form is described in particular in EP-A-1 135 125 which describes a sustained release tablet, comprising a single layer containing the active ingredient embedded in the mass of a polymeric material based on cellulose. This polymeric material, which forms in contact with aqueous media a matrix, allows a slowing down of the dissolution of the active ingredient, which can thus produce its pharmacological effect more slowly.
[0008] Le document EP-A-1 135 125 décrit également d'autres formes de réalisation de formulations à libération prolongée de zolpidem. Par exemple, il est décrit un comprimé multicouche dans lequel le zolpidem est présent dans deux entités, une entité à libération immédiate, par exemple externe, et une entité à libération prolongée, par exemple interne.[0008] EP-A-1,135,125 also discloses other embodiments of zolpidem extended release formulations. For example, there is disclosed a multilayer tablet in which zolpidem is present in two entities, an immediate release entity, for example an external entity, and a sustained release entity, for example internal.
[0009] L'entité à libération prolongée comprend une couche ou noyau de matériau polymérique, en particulier un polymère à base de cellulose, libérant la quantité de zolpidem qu'il renferme plus lentement que l'entité à libération immédiate. Selon cette forme d'exécution, le total des deux doses de zolpidem contenues dans chaque entité correspond à la dose que l'on souhaite administrer au patient.The sustained-release entity comprises a layer or core of polymeric material, particularly a cellulose-based polymer, releasing the amount of zolpidem it contains more slowly than the immediate-release entity. According to this embodiment, the total of the two doses of zolpidem contained in each entity corresponds to the dose that it is desired to administer to the patient.
[0010] Pour assurer un micro-pH suffisamment bas pour maintenir la solubilité du zolpidem indépendante du pH des milieux digestifs rencontrés, le document EP-A-1 135 125 décrit l'utilisation d'un agent acidifiant, par exemple de l'acide citrique, tartrique ou fumarique. Dans la présente demande de brevet, on entend par micro-pH local (ou pH local) le pH existant dans l'environnement immédiat de la formulation, au fur et à mesure de sa dissolution dans le tractus gastro-intestinal.To ensure a micro-pH low enough to maintain the solubility of zolpidem independent of the pH of the digestive media encountered, the document EP-A-1 135 125 describes the use of an acidifying agent, for example acid citric, tartaric or fumaric. In the present patent application, the term local micro-pH (or local pH) means the pH existing in the immediate environment of the formulation, as it dissolves in the gastrointestinal tract.
En particulier dans une portion non désintégrée de la formulation mais dans laquelle de l'eau a déjà pénétré à un temps donné.In particular in a non-disintegrated portion of the formulation but in which water has already penetrated at a given time.
[0011] Ces agents acidifiants présentent cependant l'inconvénient de pouvoir réagir, dans certaines conditions, avec le ou les polymères à base de cellulose présents dans la formulation.These acidifying agents however have the disadvantage of being able to react, under certain conditions, with the cellulose-based polymer (s) present in the formulation.
[0012] On a ainsi remarqué, lorsque la formulation est exposée à la chaleur et à l'humidité, que l'agent acidifiant pouvait provoquer une hydrolyse partielle du polymère à
base de cellulose constituant l'excipient matriciel de la formulation, conduisant à des chaînes polymériques plus courtes.It was thus noted, when the formulation is exposed to heat and moisture, that the acidifying agent could cause partial hydrolysis of the polymer to cellulose base constituting the matrix excipient of the formulation, leading to shorter polymer chains.
Cette dégradation du polymère par l'agent acidifiant peut alors conduire à une stabilité réduite des formulations, et peut obliger le fabricant à préconiser des conditions de stockage plus strictes, vis-à-vis de la chaleur et de l'humidité, ou à prévoir un système de conditionnement plus étanche.This degradation of the polymer by the acidifying agent can then lead to a reduced stability of the formulations, and may oblige the manufacturer to recommend stricter storage conditions, with respect to heat and humidity, or to provide for a more watertight packaging system.
[0013] L'invention a pour but de résoudre cet inconvénient, en proposant une formulation à libération prolongée permettant de maintenir un pH local suffisamment bas pour assurer une solubilité du principe actif indépendante du pH, et sans dégradation du polymère présent dans la matrice, ni incidence négative sur la stabilité du principe actif.The invention aims to solve this drawback by proposing a sustained release formulation to maintain a local pH low enough to ensure solubility of the active ingredient independent of pH, and without degradation of the polymer present in the matrix, nor a negative impact on the stability of the active ingredient.
[0014] Un premier objet de l'invention concerne une telle formulation à libération prolongée.A first object of the invention relates to such a sustained release formulation.
[0015] La formulation de l'invention pour une libération prolongée d'un principe actif présentant une solubilité dépendante du pH comprend un excipient matriciel à base de polymère hydrophile qui renferme une dose déterminée de principe actif, et se caractérise en ce qu'elle comprend un ou plusieurs agents acidifiants sous forme d'un sel acide d'un acide organique.The formulation of the invention for a sustained release of an active ingredient having a pH-dependent solubility comprises a matrix excipient based on hydrophilic polymer which contains a determined dose of active ingredient, and is characterized in that it comprises one or more acidifying agents in the form of an acidic salt of an organic acid.
Le sel acide de l'agent acidifiant peut être par exemple un sel acide de l'acide citrique, tartrique, fumarique, succinique ou malique, ainsi que les mélanges de ceux-ci.The acidic salt of the acidifying agent may be, for example, an acidic salt of citric, tartaric, fumaric, succinic or malic acid, as well as mixtures thereof.
[0016] On a en effet découvert que de tels agents acidifiants, tout en permettant de maintenir un pH local bas, et d'assurer ainsi une libération du principe actif indépendante du pH, ne provoquaient pas de dégradation de la matrice polymérique hydrophile avec laquelle ils sont en contact.It has indeed been found that such acidifying agents, while allowing to maintain a low local pH, and thus ensure a release of the active ingredient independent of pH, do not cause degradation of the hydrophilic polymer matrix with which they are in contact.
[0017] Des exemples d'agent acidifiant sous forme de sel acide sont le tartrate monopotassique (ou bitartrate potassique), le tartrate monosodique, le citrate monosodique, le citrate bisodique, et/ou les mélanges de ceux-ci. Parmi les sels acides ci-dessus, le tartrate monopotassique présente de plus l'avantage de ne pas avoir d'influence sur la stabilité du tartrate ou de l'hémitartrate de zolpidem.Examples of acidifying agent in the form of acidic salt are monopotassic tartrate (or potassium bitartrate), monosodium tartrate, monosodium citrate, bisodium citrate, and / or mixtures thereof. Among the above acidic salts, monopotassium tartrate has the additional advantage of not having any influence on the stability of tartrate or zolpidem hemitartrate.
[0018] Le pourcentage d'agent acidifiant est compris entre environ 2 % et environ 10 % en poids, calculé par rapport au poids total de la formulation, par exemple entre environ 4
% et environ 8 % en poids.The percentage of acidifying agent is between about 2% and about 10% by weight, calculated with respect to the total weight of the formulation, for example between about 4 % and about 8% by weight.
[0019] II va de soi que l'invention ne se limite pas à la formulation de zolpidem. D'autres principes actifs dont la solubilité dépend du pH environnant peuvent être utilisés dans le cadre de l'invention. Ceci est le cas notamment pour des principes actifs basiques, présents dans la formulation sous forme de base libre ou de sel, ces principes actifs étant insolubles ou faiblement solubles en milieu aqueux à pH neutre, et quand la valeur de pKa est supérieure à 2.It goes without saying that the invention is not limited to the formulation of zolpidem. Other active ingredients whose solubility depends on the surrounding pH can be used in the context of the invention. This is the case in particular for basic active ingredients present in the formulation in free base or salt form, these active ingredients being insoluble or poorly soluble in aqueous medium at neutral pH, and when the pKa value is greater than 2.
[0020] Par exemple, d'autres principes actifs utilisables avec l'invention sont le N-[2-[(4- aminocarbonyl)pyrimidin-2-yl]amino]ethyl]-2-[[3-[4-(5-chloro-2-methoxyphenyl)piperazin- 1-yl]propyl]amino]pyrimidine-4-carboximide, le chlorhydrate de 5-(8-amino-7-chloro-2,3- dihydro-1 ,4-benzodioxin-5-yl)-3-[1 -(2-phenylethyl)piperidin-4-yl]-1 ,3,4-oxodiazol-2(3H)- one, la 7-fluoro-2-oxo-4-[2-[4-(thieno-[3,2-c]-pyridin-4-yl)piperazin-1-yl]ethyl]-1 ,2- dihydroquinoline-1-acetamide, le clopidogrel, la mizolastine.For example, other active ingredients that can be used with the invention are N- [2 - [(4-aminocarbonyl) pyrimidin-2-yl] amino] ethyl] -2 - [[3- [4- 5-chloro-2-methoxyphenyl) piperazin-1-yl] propyl] amino] pyrimidine-4-carboximide, 5- (8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin) hydrochloride. 5-yl) -3- [1- (2-phenylethyl) piperidin-4-yl] -1,3,4-oxodiazol-2 (3H) -one, 7-fluoro-2-oxo-4- [2-yl] -3- [1- (2-phenylethyl) piperidin-4-yl] -1,3,4-oxodiazol-2 (3H) -one; [4- (thieno- [3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl] -1,2-dihydroquinoline-1-acetamide, clopidogrel, mizolastine.
[0021] Les principes actifs utilisables dans le cadre de l'invention peuvent exister sous forme de base, d'un sel d'addition, notamment un sel acide, d'hydrate ou de solvate, à savoir sous forme d'associations ou de combinaisons avec une ou plusieurs molécules d'eau ou avec un solvant.The active ingredients that can be used in the context of the invention may exist in the form of a base, an addition salt, in particular an acidic salt, a hydrate or a solvate salt, namely in the form of associations or combinations with one or more molecules of water or with a solvent.
Par exemple, le zolpidem peut être utilisé sous forme d'hémitartrate.For example, zolpidem can be used in the form of hemitartrate.
[0022] La formulation de l'invention comprend un excipient matriciel permettant une libération prolongée du principe actif. A titre d'exemples d'excipient matriciel à base de polymère hydrophile, on peut citer la cellulose et ses dérivés, par exemple Phydroxypropylméthylcellulose (hypromellose), l'hydroxyéthylcellulose,The formulation of the invention comprises a matrix excipient allowing prolonged release of the active ingredient. Examples of hydrophilic polymer-based matrix excipients that may be mentioned include cellulose and its derivatives, for example hydroxypropylmethylcellulose (hypromellose), hydroxyethylcellulose,
Phydroxypropylcellulose, la carboxyméthylcellulose, les gommes végétales et leurs dérivés, les dérivés de l'acide alginique, l'amidon et ses dérivés.Hydroxypropylcellulose, carboxymethylcellulose, vegetable gums and their derivatives, derivatives of alginic acid, starch and its derivatives.
[0023] La formulation à libération prolongée de l'invention comprend en outre les ingrédients classiques utilisés dans ce type de formulation.The sustained-release formulation of the invention further comprises the conventional ingredients used in this type of formulation.
Ainsi, la formulation de l'invention peut comprendre un ou plusieurs agents diluants, agents désagrégeants, agents liants, lubrifiants, excipients d'écoulement, agents colorants choisis parmi ceux connus de l'homme du métier.Thus, the formulation of the invention may comprise one or more diluents, disintegrating agents, binding agents, lubricants, flow excipients, coloring agents chosen from those known to those skilled in the art.
[0024] A titre d'exemples d'agents diluants, on peut citer le lactose et ses dérivés, par
exemple le lactose monohydraté, la cellulose et ses dérivés, par exemple la cellulose microcristalline, le mannitol, l'hydrogéno-phosphate de calcium, le phosphate tricalcique, le sulfate de calcium, l'amidon et ses dérivés, notamment l'amidon prégélatinisé, l'amidon réticulé.By way of examples of diluents, mention may be made of lactose and its derivatives, for example lactose monohydrate, cellulose and its derivatives, for example microcrystalline cellulose, mannitol, calcium hydrogen phosphate, tricalcium phosphate, calcium sulphate, starch and its derivatives, in particular pregelatinized starch, crosslinked starch.
[0025] A titre d'exemples d'agents liants, on peut citer l'hydroxypropylméthylcellulose de bas poids moléculaire et ses dérivés, par exemple le Methocel® E5, les povidones par exemple le Kollidon K30.As examples of binding agents, mention may be made of hydroxypropyl methylcellulose of low molecular weight and its derivatives, for example Methocel ® E5, povidones for example Kollidon K30.
[0026] A titre d'exemples d'agents désagrégeants, on peut citer l'amidon et ses dérivés, par exemple la carboxyméthylamidon sodique, la povidone réticulée, le croscarmellose, l'hydroxypropylcellulose de bas poids moléculaire.Examples of disintegrating agents include starch and its derivatives, for example sodium carboxymethyl starch, crosslinked povidone, croscarmellose, hydroxypropylcellulose low molecular weight.
[0027] A titre d'exemples d'agents lubrifiants, on peut citer l'acide stéarique et ses sels, par exemple, le stéarate de magnésium, le fumarate stéaryle de sodium, le behenate de glycéryle.As examples of lubricating agents include stearic acid and its salts, for example, magnesium stearate, sodium stearyl fumarate, glyceryl behenate.
[0028] A titre d'exemples d'excipients d'écoulement, on peut citer la silice et ses dérivés par exemple la silice colloïdale anhydre, le dioxyde de silicium colloïdal, le talc.As examples of flow excipients, there may be mentioned silica and its derivatives, for example anhydrous colloidal silica, colloidal silicon dioxide, talc.
[0029] A titre d'exemples d'agents colorants, on peut citer les oxydes métalliques, par exemple les oxydes de fer, notamment de fer rouge ou jaune, l'indigotine, le curcumin, la riflavine, la tartrazine, l'azorubine, les carminés, l'erythosine, le rouge 2G, le bleu patenté V, les chlorophylles, les complexes de cuivre de chlorophylle, les caroténoïdes, les extraits de paprika, les anthocyanes, le dioxyde de titane, l'aluminium, l'argent, l'or, ainsi que les autres agents colorants pharmaceutiquement acceptables.By way of examples of coloring agents, mention may be made of metal oxides, for example iron oxides, in particular red or yellow iron, indigotine, curcumin, riflavin, tartrazine and azorubine. , carminates, erythosine, red 2G, patent blue V, chlorophylls, chlorophyll copper complexes, carotenoids, paprika extracts, anthocyanins, titanium dioxide, aluminum, silver gold, as well as other pharmaceutically acceptable coloring agents.
[0030] Selon une forme d'exécution, la formulation de l'invention comprend une couche de pelliculage. Cette couche de pelliculage peut comprendre un ou plusieurs agents opacifiants, agents plastifiants, colorants, ainsi qu'un ou plusieurs excipients, polymères filmogènes.According to one embodiment, the formulation of the invention comprises a film-coating layer. This film-coating layer may comprise one or more opacifying agents, plasticizing agents, dyes, as well as one or more excipients, film-forming polymers.
[0031] Ces ingrédients sont choisis parmi ceux connus de l'homme du métier. A titre d'exemples d'agents opacifiants, on peut citer l'oxyde de titane; à titre d'exemples d'agents plastifiants, on peut citer le polyéthylène glycol et ses dérivés; à titre d'exemples
d'excipients, on peut citer le lactose et ses dérivés, par exemple le lactose monohydraté. A titre d'exemples d'excipients polymères filmogènes, on peut citer l'hydroxypropyléthylcellulose, l'alcool polyvinylique.These ingredients are chosen from those known to those skilled in the art. As examples of opacifying agents, mention may be made of titanium oxide; examples of plasticizers include polyethylene glycol and its derivatives; as examples excipients, mention may be made of lactose and its derivatives, for example lactose monohydrate. As examples of film-forming polymer excipients, mention may be made of hydroxypropylethylcellulose and polyvinyl alcohol.
[0032] De façon générale, la formulation de l'invention comprend une entité à libération prolongée et, éventuellement, une entité à libération immédiate.In general, the formulation of the invention comprises a sustained release entity and, optionally, an immediate release entity.
[0033] Selon l'invention, on entend par entité à libération immédiate une dose comprenant une quantité déterminée de principe actif à libération immédiate, telle que par exemple un comprimé ou un pellet à libération immédiate, ou plusieurs des ces doses formulées dans une gélule ou un comprimé; une matrice à libération immédiate dans un comprimé; une couche à libération immédiate dans un comprimé multicouche; une couche d'enrobage à libération immédiate dans un comprimé enrobé.According to the invention, the immediate release entity is understood to mean a dose comprising a specific quantity of immediate-release active ingredient, such as, for example, an immediate-release tablet or pellet, or a plurality of these doses formulated in a capsule. or a tablet; an immediate release matrix in a tablet; an immediate release layer in a multilayer tablet; an immediate release coating layer in a coated tablet.
[0034] On entend par entité à libération prolongée une dose comprenant une dose déterminée de principe actif à libération prolongée, telle qu'un comprimé à libération prolongée, ou plusieurs des ces doses formulées dans une gélule ou un comprimé; une matrice à libération prolongée dans un comprimé; une couche à libération prolongée dans un comprimé multicouche.By sustained release entity is meant a dose comprising a fixed dose of sustained-release active ingredient, such as a sustained-release tablet, or more of these doses formulated in a capsule or tablet; a sustained release matrix in a tablet; a sustained release layer in a multilayered tablet.
[0035] Les formes unitaires d'administration de la formulation de l'invention comprennent les formes par voie orale telles que les comprimés, notamment les comprimés multicouche, enrobés, à noyau; les gélules molles ou dures.The unit dosage forms of the formulation of the invention include oral forms such as tablets, including multilayer, coated, core tablets; soft or hard capsules.
[0036] Selon une forme d'exécution, la formulation de l'invention consiste en un comprimé multicouche, notamment un comprimé à deux couches.According to one embodiment, the formulation of the invention consists of a multilayer tablet, in particular a two-layer tablet.
[0037] La première couche est à libération immédiate et comprend une dose de zolpidem, délivrant par désintégration rapide au contact de l'eau la totalité du zolpidem qu'elle renferme.The first layer is immediate release and comprises a dose of zolpidem, delivering by rapid disintegration in contact with water all of zolpidem it contains.
La seconde couche est à libération prolongée et referme également une dose de zolpidem, délivrant progressivement le principe actif par érosion et diffusion. Les teneurs en principe actif de chacune des deux couches peuvent varier, généralement les doses respectives sont sensiblement de même grandeur.The second layer is sustained release and also closes a dose of zolpidem, gradually delivering the active ingredient by erosion and diffusion. The contents of the active ingredient of each of the two layers may vary, generally the respective doses are of substantially the same size.
[0038] Par exemple, la couche à libération immédiate peut contenir de 40 à 55 % de la
dose totale de principe actif contenue dans la formulation, par exemple 48 % de principe actif, et la couche à libération prolongée peut contenir de 45 à 60 % de la dose totale de principe actif contenu dans la formulation, par exemple 52 %.For example, the immediate release layer may contain from 40 to 55% of the total dose of active ingredient contained in the formulation, for example 48% of active ingredient, and the sustained-release layer may contain from 45 to 60% of the total dose of active ingredient contained in the formulation, for example 52%.
[0039] Ainsi, selon une forme d'exécution, la formulation de l'invention comprend :Thus, according to one embodiment, the formulation of the invention comprises:
- une première couche à libération immédiate comprenant un principe actif dont la solubilité est dépendante du pH, et un ou plusieurs agents liants, la première couche comportant éventuellement un ou plusieurs autres excipients tels que agents diluants, agents désagrégeants, agents lubrifiants, agents colorants ; - une seconde couche à libération prolongée, adjacente à la première couche, comprenant un principe actif dont la solubilité est dépendante du pH, un ou plusieurs agents acidifiants sous forme de sel acide et un ou plusieurs excipients matriciels, la seconde couche comportant éventuellement un ou plusieurs autres excipients tels que agents diluants, agents liants, agents lubrifiants, agents colorants.a first immediate release layer comprising an active ingredient whose solubility is dependent on the pH, and one or more binding agents, the first layer optionally comprising one or more other excipients such as diluents, disintegrating agents, lubricating agents, coloring agents; a second sustained-release layer, adjacent to the first layer, comprising an active ingredient whose solubility is dependent on the pH, one or more acidifying agents in the acid salt form and one or more matrix excipients, the second layer optionally comprising one or more several other excipients such as diluents, binding agents, lubricating agents, coloring agents.
[0040] Selon une forme d'exécution, la première couche à libération immédiate comprend, en pourcentage en poids par rapport au poids total de la couche considérée :According to one embodiment, the first immediate release layer comprises, in percentage by weight relative to the total weight of the layer in question:
- de 1 % à 10 % en poids d'hémitartrate de zolpidem,from 1% to 10% by weight of zolpidem hemitartrate,
- de 50 % à 95 % en poids d'agent diluant, - de 0 % à 10 % en poids d'agent désagrégeant,from 50% to 95% by weight of diluent, from 0% to 10% by weight of disintegrant,
- de 0 % à 5 % en poids d'agent liant,from 0% to 5% by weight of binding agent,
- de 0,5 % à 2,5 % en poids d'agent lubrifiant,from 0.5% to 2.5% by weight of lubricating agent,
- de 0 % à 0,5 % en poids d'agent d'écoulement,from 0% to 0.5% by weight of flow agent,
- de 0 % à 1 % en poids d'agent colorant.from 0% to 1% by weight of coloring agent.
[0041] Selon une forme d'exécution, la seconde couche à libération prolongée comprend, en pourcentage en poids par rapport au poids total de la couche considérée :According to one embodiment, the second extended-release layer comprises, in percentage by weight relative to the total weight of the layer in question:
- de 1 % à 10 % en poids d'hémitartrate de zolpidem,from 1% to 10% by weight of zolpidem hemitartrate,
- de 40 % à 80 % en poids d'agent diluant, - de 20 % à 50 % en poids d'excipient matriciel, de 5 % à 15 % en poids d'agent acidifiant,from 40% to 80% by weight of diluent, from 20% to 50% by weight of matrix excipient, from 5% to 15% by weight of acidifying agent,
- de 0,5 % à 2,5 % en poids d'agent lubrifiant,from 0.5% to 2.5% by weight of lubricating agent,
- de 0 % à 0,5 % en poids d'agent d'écoulement.from 0% to 0.5% by weight of flow agent.
[0042] Selon cette forme d'exécution, la formulation peut comprendre également une couche de pelliculage, enrobant la première et la seconde couches.
Cette couche de pelliculage peut être réalisée à partir de compositions disponibles commercialement, par exemple les produits commercialisés sous les dénominations OPADRY® II 32F20797, OPADRY® YS-1-1418 et comprend généralement comme ingrédients principaux un excipient de charge, un liant polymérique, un agent opacifiant, un agent plastifiant, un agent colorant et un solvant.According to this embodiment, the formulation may also comprise a film-coating layer, coating the first and the second layers. This coating layer may be made of commercially available compositions, such as products sold under the names OPADRY ® II 32F20797, OPADRY ® YS-1-1418 and generally comprises as main ingredients a load carrier, a polymeric binder, opacifying agent, a plasticizer, a coloring agent and a solvent.
[0043] Les excipients contenus dans la première et la seconde couche peuvent être identiques ou différents entre eux, à l'exception de l'agent acidifiant.The excipients contained in the first and the second layer may be identical or different from each other, with the exception of the acidifying agent.
[0044] Les compositions selon l'invention peuvent être préparées selon les méthodes connues de l'homme du métier.The compositions according to the invention may be prepared according to the methods known to those skilled in the art.
Les comprimés à libération immédiate peuvent être préparés par compression directe de mélanges des principes actifs sous forme de base ou de sels avec des diluants, tels que la cellulose microcristalline, le mannitol, le sorbitol, le lactose. D'autres excipients, tels que des désagrégeants ou des lubrifiants, peuvent être ajoutés.Immediate-release tablets may be prepared by direct compression of mixtures of active ingredients in base form or salts with diluents, such as microcrystalline cellulose, mannitol, sorbitol, lactose. Other excipients, such as disintegrants or lubricants, may be added.
Le choix entre ces excipients fonctionnels ainsi que ces diluants est bien connu de l'homme du métier.The choice between these functional excipients as well as these diluents is well known to those skilled in the art.
[0045] Selon une autre forme d'exécution, les comprimés peuvent être préparés par granulation à l'eau d'un mélange du ou des principes actifs avec les diluants, agents désagrégeants et polymère de liaison appropriés, puis calibration et séchage du granulat obtenu, addition d'un agent lubrifiant, suivie par une compression sur une machine à comprimer.According to another embodiment, the tablets may be prepared by granulation with water of a mixture of the active ingredient (s) with the appropriate diluents, disintegrating agents and binding polymer, and then calibration and drying of the granulate obtained. , addition of a lubricating agent, followed by compression on a compression machine.
[0046] Les méthodes mises en œuvre sont généralement celles décrites dans la littérature, par exemple B. B. Sheth, F. J. Bandelin, R. JF. Shangraw, Compressed tablets, dans Pharmaceutical dosage forms : Tablets, Vol 1 , édité par H. A. Lieberman and L. Lachman, Dekker N, Y. (1980).The methods used are generally those described in the literature, for example B. B. Sheth, F. J. Bandelin, R. JF. Shangraw, Compressed tablets, in Pharmaceutical Dosage Forms: Tablets, Vol 1, edited by H. A. Lieberman and L. Lachman, Dekker N, Y. (1980).
[0047] Les comprimés à libération prolongée peuvent être préparés par incorporation d'excipients matriciels dans la formulation, sans agents désagrégeants. De tels excipients matriciels sont par exemple les polymères hydrophiles décrits ci-dessus, par exemple à base de cellulose, qui gonflent en contact avec l'eau et libèrent de façon prolongée le principe actif par diffusion au travers du réseau de polymère gonflé.The sustained release tablets may be prepared by incorporation of matrix excipients into the formulation without disintegrating agents. Such matrix excipients are, for example, the hydrophilic polymers described above, for example based on cellulose, which swell in contact with water and prolongively release the active principle by diffusion through the swollen polymer network.
[0048] Les méthodes pour préparer des comprimés à plusieurs couches ou à plusieurs
enrobages sont décrites par W. C. Gunsel, compression coated and layer tablets in pharmaceutical dosage forms: Tablets, vol 1, édité par H. A. Lieberman et L. Lachman, Dekker N. Y. (1980).Methods for preparing multi-layered or multi-layered tablets Coatings are described by WC Gunsel, compression coated and layer tablets in pharmaceutical dosage forms: Tablets, vol. 1, edited by HA Lieberman and L. Lachman, Dekker NY (1980).
Exemple 1. Préparation d'un comprimé à deux couches, contenant une dose de 6,25 mg de zolpidem.Example 1. Preparation of a two-layer tablet containing a dose of 6.25 mg zolpidem.
[0049] On prépare selon les techniques décrites ci-dessus un comprimé présentant la composition indiquée dans le tableau I ci-après.Preparing according to the techniques described above a tablet having the composition shown in Table I below.
Tableau ITable I
Tableau l (suite) Table l (continued)
Exemple 2. Préparation d'un comprimé à deux couches, contenant une dose de 12,5 mg de zolpidem.Example 2. Preparation of a two-layer tablet containing a dose of 12.5 mg of zolpidem.
[0050] On prépare selon les techniques décrites ci-dessus un comprimé présentant la composition indiquée dans le tableau II ci-après.Preparing according to the techniques described above a tablet having the composition shown in Table II below.
Tableau IITable II
Tableau 11 (suite) Table 11 (continued)
Exemple 3. Préparation d'un comprimé à deux couches, contenant 12,5 mg de tartrate de zolpidem et de l'acide tartrique.Example 3. Preparation of a two-layer tablet containing 12.5 mg of zolpidem tartrate and tartaric acid.
[0051] On prépare selon les techniques décrites ci-dessus un comprimé présentant la composition indiquée dans le tableau III ci-après.Preparing according to the techniques described above a tablet having the composition shown in Table III below.
TableauBoard
Tableau III (suite) Table III (continued)
Exemple 4. Etude de stabilité des formulations de l'invention.Example 4. Stability study of the formulations of the invention.
[0052] La stabilité des formulations selon l'invention est comparée à celle d'une formulation préparée selon l'exemple 3.The stability of the formulations according to the invention is compared with that of a formulation prepared according to Example 3.
Les conditions expérimentales sont les suivantes:
- appareil à panierThe experimental conditions are as follows: - basket device
- milieu de dissolution: 500 ml d'HCI 0,01 M dégazédissolution medium: 500 ml of degassed 0.01 M HCI
- vitesse de rotation: 100 tpm- rotational speed: 100 rpm
- température: 37°C, 0,5 0C - prise d'essai: un comprimé à analyser par récipient- temperature: 37 ° C, 0,5 ° C - test portion: one tablet to be analyzed per container
- temps de dissolution: 6 heures- dissolution time: 6 hours
- prélèvements: en continu- samples: continuously
- lecture: toutes les 5 minutes jusqu'à 30 minutes, puis toutes les 15 minutes jusqu'à 6 heures - dosage: par spectrophotométrie U.V. à 295 nm (cuve: 10 mm, filtre: 0,22 μm)- reading: every 5 minutes up to 30 minutes, then every 15 minutes up to 6 hours - assay: by U.V spectrophotometry at 295 nm (tank: 10 mm, filter: 0.22 μm)
- étalon: solution à 25 mg / 1 de tartrate de zolpidem exprimée en tartrate anhydre, étalon de travail, dans HCI 0,01 M.- standard: 25 mg / 1 solution of zolpidem tartrate expressed as anhydrous tartrate, working standard, in 0.01 M HCI.
[0053] Les résultats obtenus sont représentés sur les figures 1 et 2, dans lesquelles la figure 1 représente l'évolution des profils de dissolution en fonction du temps, obtenue avec la formulation préparée selon l'exemple 3 (comprimé de zolpidem à 12,5 mg contenant comme agent acidifiant de l'acide tartrique), et la figure 2 représente révolution des profils de dissolution en fonction du temps, obtenue avec la formulation préparée selon l'exemple 2 (comprimé de zolpidem à 12,5 mg contenant comme agent acidifiant du tartrate monopotassique).The results obtained are represented in FIGS. 1 and 2, in which FIG. 1 represents the evolution of the dissolution profiles as a function of time, obtained with the formulation prepared according to example 3 (zolpidem tablet at 12, 5 mg containing as acidifying agent of tartaric acid), and FIG. 2 represents revolution of the dissolution profiles as a function of time, obtained with the formulation prepared according to Example 2 (12.5 mg zolpidem tablet containing as agent acidifier of monopotassium tartrate).
[0054] II apparaît que la formulation de l'exemple 2 présente une stabilité à la chaleur et à l'humidité supérieure à celle de la formulation préparée selon l'exemple 3.
It appears that the formulation of Example 2 has a stability to heat and moisture greater than that of the formulation prepared according to Example 3.
Claims
1. Formulation à libération prolongée, utilisable avec un principe actif présentant une solubilité dépendante du pH, comprenant un excipient matriciel à base de polymère hydrophile, l'excipient matriciel renfermant une dose déterminée de principe actif, caractérisée en ce qu'elle comprend un ou plusieurs agents acidifiants sous forme d'un sel acide d'un acide organique.1. Sustained-release formulation, usable with an active ingredient having a pH-dependent solubility, comprising a hydrophilic polymer-based matrix excipient, the matrix excipient containing a determined dose of active ingredient, characterized in that it comprises one or more several acidifying agents in the form of an acidic salt of an organic acid.
2. Formulation selon la revendication 1 , caractérisée en ce que le sel acide de l'agent acidifiant est un sel acide de l'acide citrique, tartrique, fumarique, succinique ou malique, ainsi que les mélanges de ceux-ci.2. Formulation according to claim 1, characterized in that the acidic salt of the acidifying agent is an acidic salt of citric, tartaric, fumaric, succinic or malic acid, and the mixtures thereof.
3. Formulation selon la revendication 2, caractérisée en ce que le sel acide de l'agent acidifiant est le tartrate monopotassique, le tartrate monosodique, le citrate monosodique, le citrate bisodique, et/ou les mélanges de ceux-ci.3. Formulation according to claim 2, characterized in that the acidic salt of the acidifying agent is monopotassic tartrate, monosodium tartrate, monosodium citrate, bisodic citrate, and / or mixtures thereof.
4. Formulation selon la revendication 2 ou 3, caractérisée en ce que le pourcentage d'agent acidifiant est compris entre environ 2 % et environ 10 % en poids, par exemple entre environ 4 % et environ 8 % en poids par rapport au poids total de la formulation.4. Formulation according to claim 2 or 3, characterized in that the percentage of acidifying agent is between about 2% and about 10% by weight, for example between about 4% and about 8% by weight relative to the total weight of the formulation.
5. Formulation selon l'une quelconque des revendications 1 à 4, caractérisée en ce que le principe actif est choisi parmi le zolpidem, le N-[2-[(4-aminocarbonyl)pyrimidin-2- yl]amino]ethyl]-2-[[3-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]propyl]amino]pyrimidine- 4-carboximide, le chlorhydrate de 5-(8-amino-7-chloro-2,3-dihydro-1 ,4-benzodioxin-5-yl)- 3-[1-(2-phenylethyl)piperidin-4-yl]-1 ,3,4-oxodiazol-2(3H)-one, la 7-fluoro-2-oxo-4-[2-[4- (thieno-[3,2-c]-pyridin-4-yl)piperazin-1 -yl]ethyl]-1 ,2-dihydroquinoline-1 -acetamide, le clopidogrel, la mizolastine.5. Formulation according to any one of claims 1 to 4, characterized in that the active principle is selected from zolpidem, N- [2 - [(4-aminocarbonyl) pyrimidin-2-yl] amino] ethyl] - 2 - [[3- [4- (5-chloro-2-methoxyphenyl) piperazin-1-yl] propyl] amino] pyrimidine-4-carboximide, 5- (8-amino-7-chloro-2) hydrochloride, 3-Dihydro-1,4-benzodioxin-5-yl) -3- [1- (2-phenylethyl) piperidin-4-yl] -1,3,4-oxodiazol-2 (3H) -one, 7- fluoro-2-oxo-4- [2- [4- (thieno- [3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl] -1,2-dihydroquinoline-1-acetamide, clopidogrel, mizolastine.
6. Formulation selon l'une quelconque des revendications 1 à 5, caractérisée en ce que le sel acide de l'agent acidifiant est le tartrate monopotassique et en ce que le principe actif est Phémitartrate de zolpidem.6. Formulation according to any one of claims 1 to 5, characterized in that the acidic salt of the acidifying agent is monopotassic tartrate and in that the active ingredient is zolpidem semitartrate.
7. Formulation selon l'une quelconque des revendications 1 à 6, caractérisée en ce que le polymère formant l'excipient matriciel est choisi parmi la cellulose et ses dérivés, par exemple l'hydroxypropylméthylcellulose, Phydroxyéthylcellulose, l'hydroxypropylcellulose, la carboxyméthylcellulose, les gommes végétales et leurs dérivés, les dérivés de l'acide alginique, l'amidon et ses dérivés.7. Formulation according to any one of claims 1 to 6, characterized in that the polymer forming the matrix excipient is selected from cellulose and its derivatives, for example hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, vegetable gums and their derivatives, acid derivatives alginic, starch and its derivatives.
8. Formulation selon l'une quelconque des revendications 1 à 7, caractérisée en ce qu'elle comprend un ou plusieurs agents diluants, agents désagrégeants, agents liants, lubrifiants, excipients d'écoulement, agents colorants.8. Formulation according to any one of claims 1 to 7, characterized in that it comprises one or more diluents, disintegrating agents, binding agents, lubricants, flow excipients, coloring agents.
9. Formulation selon l'une quelconque des revendications 1 à 8, caractérisée en ce qu'elle comprend :9. Formulation according to any one of claims 1 to 8, characterized in that it comprises:
- une première couche à libération immédiate comprenant un principe actif dont la solubilité est dépendante du pH, et un ou plusieurs agents liants, la première couche comportant éventuellement un ou plusieurs autres excipients tels que agents diluants, agents désagrégeants, agents lubrifiants, agents colorants ;a first immediate release layer comprising an active ingredient whose solubility is dependent on the pH, and one or more binding agents, the first layer optionally comprising one or more other excipients such as diluents, disintegrating agents, lubricating agents, coloring agents;
- une seconde couche à libération prolongée, adjacente à la première couche, comprenant un principe actif dont la solubilité est dépendante du pH, un ou plusieurs agents acidifiants sous forme de sel acide et un ou plusieurs excipients matriciels, la seconde couche comportant éventuellement un ou plusieurs autres excipients tels que agents diluants, agents liants, agents lubrifiants, agents colorants.a second sustained-release layer, adjacent to the first layer, comprising an active ingredient whose solubility is dependent on the pH, one or more acidifying agents in the acid salt form and one or more matrix excipients, the second layer optionally comprising one or more several other excipients such as diluents, binding agents, lubricating agents, coloring agents.
10. Formulation selon la revendication 9, caractérisée en ce que la première couche à libération immédiate comprend, en pourcentage en poids par rapport au poids total de la couche considérée : de 1 % à 10 % en poids d'hémitartrate de zolpidem,10. Formulation according to claim 9, characterized in that the first immediate release layer comprises, in percentage by weight relative to the total weight of the layer in question: from 1% to 10% by weight of zolpidem hemitartrate,
- de 50 % à 95 % en poids d'agent diluant,from 50% to 95% by weight of diluent,
- de 0 % à 10 % en poids d'agent désagrégeant, - de 0 % à 5 % en poids d'agent liant, de 0,5 % à 2,5 % en poids d'agent lubrifiant, de 0 % à 0,5 % en poids d'agent d'écoulement,from 0% to 10% by weight of disintegrating agent, from 0% to 5% by weight of binding agent, from 0.5% to 2.5% by weight of lubricating agent, from 0% to 0% by weight 5% by weight of flow agent,
- de 0 % à 1 % en poids d'agent colorant.from 0% to 1% by weight of coloring agent.
11. Formulation selon la revendication 9, caractérisée en ce que la seconde couche à libération prolongée comprend, en pourcentage en poids par rapport au poids total de la couche considérée :11. Formulation according to claim 9, characterized in that the second extended-release layer comprises, in percentage by weight relative to the total weight of the layer in question:
- de 1 % à 10 % en poids d'hémitartrate de zolpidem,from 1% to 10% by weight of zolpidem hemitartrate,
- de 40 % à 80 % en poids d'agent diluant, - de 20 % à 50 % en poids d'excipient matriciel,from 40% to 80% by weight of diluent, from 20% to 50% by weight of matrix excipient,
- de 5 % à 15 % en poids d'agent acidifiant, - de 0,5 % à 2,5 % en poids d'agent lubrifiant,from 5% to 15% by weight of acidifying agent, from 0.5% to 2.5% by weight of lubricating agent,
- de 0 % à 0,5 % en poids d'agent d'écoulement.from 0% to 0.5% by weight of flow agent.
12. Formulation selon la revendication 9, caractérisée en ce qu'elle comprend une couche de pelliculage, comprenant comme ingrédients principaux un excipient de charge, un liant polymérique, un agent opacifiant, un agent plastifiant, un agent colorant et un solvant.12. Formulation according to claim 9, characterized in that it comprises a film-coating layer comprising, as main ingredients, a filler excipient, a polymeric binder, an opacifying agent, a plasticizer, a coloring agent and a solvent.
13. Formulation selon l'une quelconque des revendications 1 à 12, caractérisée en ce qu'elle comprend :13. Formulation according to any one of claims 1 to 12, characterized in that it comprises:
- une première couche à libération immédiate comprenant, exprimé en pourcentage en poids par rapport au poids de la première couche :a first immediate release layer comprising, expressed as a percentage by weight relative to the weight of the first layer:
- 4,8 % d'hémitartrate de zolpidem,4.8% of zolpidem hemitartrate,
- 67,65 % de lactose monohydraté, - 20,0 % de cellulose microcristalline,- 67.65% lactose monohydrate, - 20.0% microcrystalline cellulose,
- 3,8 % de carboxyméthylamidon sodique,3.8% of sodium carboxymethyl starch,
- 2,5 % d'hydroxypropylméthylcellulose 6 m. Pa. s, - 1 ,0 % de stéarate de magnésium,2.5% hydroxypropyl methylcellulose 6 m. Pa.s, - 1.0% magnesium stearate,
- 0,2 % de silice colloïdale anhydre, - 0,049 % d'oxyde de fer,0.2% colloidal anhydrous silica, 0.049% iron oxide,
- eau purifiée q. s.- purified water q. s.
- une seconde couche à libération prolongée comprenant, exprimé en pourcentage en poids par rapport au poids de la seconde couche :a second prolonged-release layer comprising, expressed as a percentage by weight relative to the weight of the second layer:
- 5,2 % d'hémitartrate de zolpidem, - 40,6 % de lactose monohydraté,- 5.2% zolpidem hemitartrate, - 40.6% lactose monohydrate,
- 25,0 % d'hydroxypropylméthylcellulose 4000 m.Pa.s,25.0% of hydroxypropylmethylcellulose 4000 m.Pa.s,
- 20,0 % de cellulose microcristalline,20.0% of microcrystalline cellulose,
- 8,0 % de tartrate monopotassique, - 1 ,0 % de stéarate de magnésium, - 0,2 % de silice colloïdale anhydre,- 8.0% of monopotassium tartrate, - 1.0% of magnesium stearate, - 0.2% of anhydrous colloidal silica,
- eau purifiée q. s.- purified water q. s.
- une couche de pelliculage comprenant, exprimé en pourcentage en poids par rapport au poids de la couche de pelliculage :a film-coating layer comprising, expressed as a percentage by weight relative to the weight of the film-coating layer:
- 36,0 % de lactose monohydraté, - 28,0 % d'hydroxypropylméthylcellulose 15 m.Pa.s,36.0% lactose monohydrate, 28.0% hydroxypropylmethylcellulose 15 m.Pa.s,
- 20,54 % d'oxyde de titane, - 10,0 % de polyéthylène glycol 3350,20.54% of titanium oxide, 10.0% of polyethylene glycol 3350,
- 5,46 % d'indigotine,- 5.46% indigotine,
- eau purifiée q. s.- purified water q. s.
14. Formulation selon l'une quelconque des revendications 1 à 12, caractérisée en ce qu'elle comprend :14. Formulation according to any one of claims 1 to 12, characterized in that it comprises:
- une première couche à libération immédiate comprenant, exprimé en pourcentage en poids par rapport au poids de la première couche :a first immediate release layer comprising, expressed as a percentage by weight relative to the weight of the first layer:
- 2,4 % d'hémitartrate de zolpidem, - 70,05 % de lactose monohydraté,- 2,4% zolpidem hemitartrate, - 70,05% lactose monohydrate,
- 20,0 % de cellulose microcristalline,20.0% of microcrystalline cellulose,
- 3,8 % de carboxyméthylamidon sodique,3.8% of sodium carboxymethyl starch,
- 2,5 % d'hydroxypropylméthylcellulose 6 m.Pa.s, - 1 ,0 % de stéarate de magnésium, - 0,2 % de silice colloïdale anhydre,2.5% hydroxypropyl methylcellulose 6 m.Pa.s, 1.0% magnesium stearate, 0.2% anhydrous colloidal silica,
- 0,049 % d'oxyde de fer,- 0.049% iron oxide,
- eau purifiée q. s.- purified water q. s.
- une seconde couche à libération prolongée comprenant, exprimé en pourcentage en poids par rapport au poids de la seconde couche : - 2,6 % d'hémitartrate de zolpidem,a second sustained-release layer comprising, expressed as a percentage by weight relative to the weight of the second layer: 2.6% of zolpidem hemitartrate,
- 38,2 % de lactose monohydraté,- 38.2% lactose monohydrate,
- 30,0 % d'hydroxypropylméthylcellulose 4000 m.Pa.s,30.0% of hydroxypropyl methylcellulose 4000 m.Pa.s,
- 20,0 % de cellulose microcristalline,20.0% of microcrystalline cellulose,
- 8,0 % de tartrate monopotassique, - 1 ,0 % de stéarate de magnésium,- 8.0% of monopotassium tartrate, - 1.0% of magnesium stearate,
- 0,2 % de silice colloïdale anhydre,0.2% of anhydrous colloidal silica,
- eau purifiée q. s.- purified water q. s.
- une couche de pelliculage comprenant, exprimé en pourcentage en poids par rapport au poids de la couche de pelliculage : - 36,0 % de lactose monohydraté,a film-coating layer comprising, expressed as a percentage by weight relative to the weight of the film-coating layer: 36.0% lactose monohydrate,
- 28,0 % d'hydroxypropylméthylcellulose 15 m.Pa.s,28.0% of hydroxypropyl methylcellulose 15 m.Pa.s,
- 24,63 % d'oxyde de titane,24.63% of titanium oxide,
- 10,0 % de polyéthylène glycol 3350, - 1 ,37 % d'oxyde de fer, - eau purifiée q. s. - 10.0% polyethylene glycol 3350, -1.37% iron oxide, - purified water qs
15. Formulation selon l'une quelconque des revendications 1 à 14, caractérisée en ce qu'elle se présente sous la forme d'un comprimé, par exemple un comprimé multicouche, enrobé, à noyau; d'une gélule molle ou dure. 15. Formulation according to any one of claims 1 to 14, characterized in that it is in the form of a tablet, for example a multilayer, coated, core compact; soft or hard capsule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0506539A FR2887455B1 (en) | 2005-06-28 | 2005-06-28 | FORMULATION WITH PROLONGED RELEASE OF ACTIVE MEDICINAL PRINCIPLES |
| PCT/FR2006/001466 WO2007003746A1 (en) | 2005-06-28 | 2006-06-26 | Prolonged release formulation of active principles having a ph-dependent solubility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1904037A1 true EP1904037A1 (en) | 2008-04-02 |
Family
ID=35708770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06778663A Withdrawn EP1904037A1 (en) | 2005-06-28 | 2006-06-26 | Prolonged release formulation of active principles having a ph-dependent solubility |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20080089936A1 (en) |
| EP (1) | EP1904037A1 (en) |
| JP (1) | JP2008546830A (en) |
| KR (1) | KR101387839B1 (en) |
| CN (1) | CN101217943B (en) |
| AR (1) | AR057410A1 (en) |
| AU (1) | AU2006264856B2 (en) |
| BR (1) | BRPI0612990A2 (en) |
| CA (1) | CA2611125A1 (en) |
| CR (1) | CR9567A (en) |
| DO (1) | DOP2006000144A (en) |
| EA (1) | EA013745B1 (en) |
| EC (1) | ECSP078010A (en) |
| FR (1) | FR2887455B1 (en) |
| GT (1) | GT200600275A (en) |
| HN (1) | HN2006023741A (en) |
| IL (1) | IL187901A0 (en) |
| MA (1) | MA29560B1 (en) |
| MX (1) | MX2007016238A (en) |
| MY (1) | MY150069A (en) |
| NO (1) | NO20080420L (en) |
| NZ (1) | NZ564069A (en) |
| PA (1) | PA8682701A1 (en) |
| PE (1) | PE20070098A1 (en) |
| TN (1) | TNSN07438A1 (en) |
| TW (1) | TWI446934B (en) |
| UA (1) | UA91553C2 (en) |
| UY (1) | UY29637A1 (en) |
| WO (1) | WO2007003746A1 (en) |
| ZA (1) | ZA200711035B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| BR112014006124A2 (en) * | 2011-09-14 | 2017-04-11 | Pozen Inc | staged dosage of clopidogrel |
| IT201700011337A1 (en) * | 2017-02-02 | 2018-08-02 | S I I T S R L Servizio Int Imballaggi Termosaldanti | MULTI-LAYER COMPRESS FOR THE ADMINISTRATION OF MAGNESIUM |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2655266B1 (en) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | CIMETIDINE PHARMACEUTICAL COMPOSITIONS. |
| DE59309678D1 (en) * | 1992-01-17 | 1999-08-05 | Alfatec Pharma Gmbh | Process for the preparation of active ingredient-containing powders, granules or pellets with a framework of hydrophilic macromolecules and their use |
| EP1005863A1 (en) * | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
| WO2000040205A2 (en) * | 1999-01-05 | 2000-07-13 | Copley Pharmaceutical Inc. | Sustained release formulation with reduced moisture sensitivity |
| EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| JP4933033B2 (en) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | Controlled release composition |
| WO2005044199A2 (en) * | 2003-11-05 | 2005-05-19 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
-
2005
- 2005-06-28 FR FR0506539A patent/FR2887455B1/en not_active Expired - Fee Related
-
2006
- 2006-06-23 PA PA20068682701A patent/PA8682701A1/en unknown
- 2006-06-26 DO DO2006000144A patent/DOP2006000144A/en unknown
- 2006-06-26 MX MX2007016238A patent/MX2007016238A/en active IP Right Grant
- 2006-06-26 JP JP2008518906A patent/JP2008546830A/en active Pending
- 2006-06-26 BR BRPI0612990-0A patent/BRPI0612990A2/en not_active Application Discontinuation
- 2006-06-26 AU AU2006264856A patent/AU2006264856B2/en not_active Ceased
- 2006-06-26 MY MYPI20063017A patent/MY150069A/en unknown
- 2006-06-26 CN CN2006800231372A patent/CN101217943B/en active Active
- 2006-06-26 EA EA200800150A patent/EA013745B1/en not_active IP Right Cessation
- 2006-06-26 WO PCT/FR2006/001466 patent/WO2007003746A1/en not_active Ceased
- 2006-06-26 KR KR1020077030484A patent/KR101387839B1/en not_active Expired - Fee Related
- 2006-06-26 CA CA002611125A patent/CA2611125A1/en not_active Abandoned
- 2006-06-26 NZ NZ564069A patent/NZ564069A/en not_active IP Right Cessation
- 2006-06-26 EP EP06778663A patent/EP1904037A1/en not_active Withdrawn
- 2006-06-26 UA UAA200800914A patent/UA91553C2/en unknown
- 2006-06-26 ZA ZA200711035A patent/ZA200711035B/en unknown
- 2006-06-27 GT GT200600275A patent/GT200600275A/en unknown
- 2006-06-27 HN HN2006023741A patent/HN2006023741A/en unknown
- 2006-06-27 AR ARP060102755A patent/AR057410A1/en unknown
- 2006-06-28 TW TW095123267A patent/TWI446934B/en not_active IP Right Cessation
- 2006-06-28 PE PE2006000753A patent/PE20070098A1/en active IP Right Grant
- 2006-06-29 UY UY29637A patent/UY29637A1/en unknown
-
2007
- 2007-11-26 TN TNP2007000438A patent/TNSN07438A1/en unknown
- 2007-12-03 US US11/949,291 patent/US20080089936A1/en not_active Abandoned
- 2007-12-04 IL IL187901A patent/IL187901A0/en unknown
- 2007-12-06 CR CR9567A patent/CR9567A/en unknown
- 2007-12-13 EC EC2007008010A patent/ECSP078010A/en unknown
- 2007-12-24 MA MA30501A patent/MA29560B1/en unknown
-
2008
- 2008-01-22 NO NO20080420A patent/NO20080420L/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2007003746A1 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1011045A3 (en) | Pharmaceutical composition for controlled release of active substances. | |
| US8741350B2 (en) | Taste masked pharmaceutical composition | |
| BE1014328A7 (en) | Pharmaceutical composition oral controlled release. | |
| US8449910B2 (en) | Stable compositions of famotidine and ibuprofen | |
| EP2640365B1 (en) | Pharmaceutical composition comprising krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament | |
| WO1998047506A1 (en) | Gastric-retained pharmaceutical composition | |
| EP1118321A1 (en) | Solid pharmaceutical compositions for the controlled delivery of active substances | |
| EP2640364A1 (en) | Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases | |
| EP1904037A1 (en) | Prolonged release formulation of active principles having a ph-dependent solubility | |
| EP1465607B1 (en) | Pharmaceutical formulations with modified release | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| US20220249479A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
| US20150224056A1 (en) | Pharmaceutical compositions of ibuprofen and famotidine | |
| US20130236538A1 (en) | Pharmaceutical compositions of ibuprofen and famotidine | |
| HK1122731B (en) | Prolonged release formulation of active pharmaceutical ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080128 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| RAX | Requested extension states of the european patent have changed |
Extension state: RS Payment date: 20080128 Extension state: MK Payment date: 20080128 Extension state: HR Payment date: 20080128 Extension state: BA Payment date: 20080128 Extension state: AL Payment date: 20080128 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
| 17Q | First examination report despatched |
Effective date: 20130123 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20130803 |